Amgen rises after autoimmune drug meets late-stage trial goal

By Reuters News

** Shares of drugmaker Amgen AMGN.O rise 2.4% to $402.69

** Co says its experimental drug, dazodalibep, for Sjogren's disease met the main goal of reducing disease activity in a late-stage trial

** Sjogren's disease is an autoimmune disorder that causes dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain

** Drug showed a statistically significant and clinically meaningful improvement at week 48; most side effects were mild to moderate

** Co plans to present detailed results at an upcoming medical meeting

** Including session's move, AMGN up 23.1% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.